Grants for Biotech, Pharma, and Medtech Startups in India: The Full Landscape

Building a life sciences startup in India is structurally different from building a SaaS company. The timelines are longer (5–15 years from lab to market), the capital requirements per milestone are higher, and the regulatory pathway adds a dimension of complexity that most generalist schemes do not account for.

The non-dilutive funding landscape, however, is deeper than most founders realise. This guide maps the full stack — from early proof-of-concept grants to manufacturing incentives — with a view to what applies at each stage.

Stage 1: Proof of concept and early research

BIRAC BIG — up to ₹50 lakh

Biotechnology Ignition Grant, administered by the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology (DBT). The most accessible entry-point grant for biotech startups — no revenue requirement, open to individual innovators, startups, and small companies.

Eligible activities: Technology development, proof-of-concept research, early prototype development in any area of biotechnology — healthcare, agriculture, industrial, environmental.

Key conditions:

• Applicant must not have received prior BIRAC BIG support for the same project
• IP developed with BIG funding is subject to a revenue-sharing arrangement with BIRAC on commercialisation
• A portion of the grant (typically 15–20%) must be spent through a BIRAC-recognised incubator

Timeline: Application windows open periodically; processing time is typically 6–9 months from application to first disbursement.

DST NIDHI PRAYAS — up to ₹15 lakh

Prototype development support under the National Initiative for Developing and Harnessing Innovations (NIDHI) programme of the Department of Science and Technology. PRAYAS is not biotech-specific — it supports any hardware or deeptech prototype — but it is highly relevant for medtech startups building diagnostic devices, imaging equipment, point-of-care tools, or wearables.

Condition: The startup must be a resident company in India. Access is through NIDHI PRAYAS centres (typically within incubators) rather than a direct DBT application.

BIRAC SPARSH — up to ₹1 crore

For startups working on innovations with social impact in health, agriculture, or environment. The thematic focus is on affordable solutions for underserved populations — rural diagnostics, low-cost therapeutics, sanitation, or agricultural biotech. A startup whose innovation is genuinely aimed at the base of the pyramid should evaluate SPARSH alongside BIG.

Stage 2: Product development and scale-up

BIRAC SBIRI (Small Business Innovation Research Initiative)

Two-phase structure modelled on the US SBIR programme:

Eligibility: Indian company with a credible technology and a clear path to commercialisation. Phase 2 requires demonstrated Phase 1 results. Both phases require a collaboration with a BIRAC-recognised research institution or a CSIR/ICMR/ICAR laboratory.

SBIRI is more competitive than BIG and requires a stronger scientific foundation — peer-reviewed publications, prior R&D, or institutional collaborations significantly improve success rates.

ICMR grants for healthcare research

The Indian Council of Medical Research (ICMR) funds clinical and translational research in healthcare. Startups that are conducting clinical studies, developing diagnostic assays, or validating new therapeutics can access ICMR extramural grants — typically through a partnership with a medical institution or hospital. Pure-play startups without an institutional collaborator have limited access to ICMR funding directly.

CSIR Technology Transfer

CSIR (Council of Scientific and Industrial Research) labs hold a large portfolio of developed but un-commercialised technologies in pharmaceuticals, agrochemicals, and industrial biotech. Startups can license CSIR technology on commercial terms, sometimes with initial deferred royalty arrangements. For pharma founders, checking CSIR's available technology portfolio before investing in internal R&D is worth the time — a validated CSIR technology reduces development time and de-risks the early stage significantly.

Stage 3: Manufacturing and commercialisation

PLI for Pharmaceuticals (Bulk Drugs and APIs)

The Production Linked Incentive scheme for pharmaceuticals covers two tracks: bulk drugs (including APIs and intermediates) and a separate KSM/drug intermediates track. Incentive rate: 10–20% on incremental manufacturing sales above a baseline year, for 6 years.

Minimum investment: ₹37–94 crore depending on the category — this places it out of reach for early-stage startups, but within range for a company completing a Series B or C round and investing in manufacturing capacity.

What makes this relevant: For a startup that has developed a novel API synthesis route using Indian raw materials (a deliberate design choice in the bulk drugs PLI), the incentive on incremental production can be substantial — 10–20% on the top line of a differentiated API is significant margin.

PLI for Medical Devices

Separate scheme from pharmaceutical PLI, with more accessible investment thresholds:

• Lower bracket: ₹6.25 crore minimum investment; 5% incentive
• Mid bracket: ₹11 crore minimum investment; 5% incentive
• Upper bracket: ₹20 crore minimum investment; 5% incentive

Product coverage: CT scanners, MRI equipment, linear accelerators, cardiac implants, and a range of advanced diagnostic and therapeutic devices. A Series A-funded medtech company investing ₹6–10 crore in manufacturing equipment is within striking range of the lower bracket.

The 80% domestic value addition requirement in some device categories means that high-import-content assemblies may not qualify. Model the local content ratio before planning the application.

The R&D deduction: Section 35

Section 35 of the Income Tax Act allows companies to deduct expenditure on approved scientific research — both capital expenditure on research facilities and revenue expenditure on in-house R&D programmes.

Current rate: 100% of actual expenditure (the weighted deduction of 150–200% was removed from AY 2021-22).

For a profitable biotech or pharma company:

• Every rupee of salary for your research team is deductible as R&D expenditure under an approved programme
• Lab equipment purchased for research is fully deductible in the year of purchase (not depreciated over several years)
• Contract research payments to National Laboratories, CSIR labs, or universities may qualify under Section 35(2AA) at 100% deduction

For a loss-making startup, the Section 35 deduction increases the carried-forward loss — which will reduce taxable income in profitable years. The deduction does not create a refund.

Approval: In-house R&D facilities must be approved by the Department of Scientific and Industrial Research (DSIR) through Form DSIR-1. Without DSIR approval, the expenditure may still qualify as a regular business deduction but not as the specific R&D deduction under Section 35.

Model the Section 35 R&D deduction for your company — and identify which research expenditures qualify: Use the R&D Deduction Calculator →

The IP layer: patents and regulatory exclusivity

For biotech and pharma startups, intellectual property is not just a strategic asset — it is the primary source of defensibility. Two IP mechanisms are particularly relevant:

Patent filing with DPIIT fast-track: DPIIT-recognised startups get an 80% rebate on Indian patent filing fees and access to expedited examination. A patent application that would ordinarily take 5–7 years can be examined in 12–18 months under the fast-track stream. Filing patents early — even before commercial launch — establishes priority and strengthens the regulatory exclusivity position.

Section 54GB for IP transfer: If a founder holds patents, trade secrets, or proprietary processes in personal ownership and transfers them to the company, Section 54GB may exempt the capital gains on that transfer. This is common when a founder developed IP at a university or in a prior role and is now commercialising it through a startup. A clean IP transfer, done with a registered valuer and proper documentation, simplifies downstream licensing deals and M&A.

What is different about the biotech funding path

Three structural realities differentiate life sciences funding from generalist startup funding:

1. Grant-to-equity sequencing matters more. A biotech startup that raises equity at too early a stage (before proof-of-concept) pays a high dilution cost for capital that could have come as non-dilutive grants. Sequencing BIRAC BIG → SBIRI Phase 1 → SBIRI Phase 2 before raising equity from VCs significantly reduces dilution.

2. Institutional collaborations unlock otherwise inaccessible programmes. Most BIRAC and ICMR programmes require or strongly prefer collaboration with a research institution. Startups without academic or CSIR/ICMR partnerships should invest in building those relationships as an infrastructure decision — not as a one-time grant tactic.

3. The regulatory pathway is the hidden timeline driver. A startup that applies for CDSCO clinical trial approval without pre-meeting with CDSCO can lose 12–18 months to avoidable regulatory re-submissions. The BIRAC-ABLE incubation ecosystem includes regulatory navigation support — using it is faster than learning CDSCO requirements from scratch.

Related: BIRAC BIG vs DST NIDHI PRAYAS vs TIDE 2.0 · PLI schemes: which applies to your startup · DPIIT Recognition benefits